Quantcast

Latest Bronchodilators Stories

2014-08-26 12:27:14

Sales of the LABA/LAMA Combination Drug Class are Expected to Grow Significantly Over the Next Six Months, According to Findings from Decision Resources Group BURLINGTON, Mass., Aug. 26, 2014 /PRNewswire/ -- Decision Resources Group finds that two-thirds of surveyed pulmonologists indicate that Boehringer Ingelheim's Spiriva is the agent most likely to be replaced by GlaxoSmithKline/Theravance's first-in-class LABA/LAMA combination Anoro Ellipta. To date, surveyed physicians reported that, of...

2014-08-19 12:28:32

For U.S. Media Only RIDGEFIELD, Conn., Aug. 19, 2014 /PRNewswire/ -- Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for the fixed-dose combination (FDC) of tiotropium and olodaterol delivered via the Respimat(®) inhaler for the proposed indication of long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including...

2014-08-14 16:27:26

Committee Voted Based on Clinical Data from Eight Efficacy Trials RIDGEFIELD, Conn., Aug. 14, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted [10 yes, 3 no] that existing data supports approval of Boehringer Ingelheim's investigational tiotropium bromide inhalation spray for long-term, once-daily maintenance treatment of bronchospasm associated...

2014-06-26 12:26:45

LONDON, June 26, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Chronic Obstructive Pulmonary Disorder (COPD) - KOL Insight and Consensus Outlookhttp://www.reportbuyer.com/pharma_healthcare/therapeutic/chronic_obstructive_pulmonary_disorder_copd_kol_insight_consensus_outlook.html The prevalence of Chronic Obstructive Pulmonary Disorder (COPD) is increasing globally, its impact on the wider health economy is significant and there remains considerable...

2014-06-03 12:37:54

LONDON, June 3, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Asthma and COPD Therapies: World Market 2013-2023http://www.reportbuyer.com/pharma_healthcare/diseases/asthma/asthma_copd_therapies.html Report DetailsNew study reveals sales potential of this large, expanding marketSee what the future holds for asthma and COPD therapies. Visiongain's report gives you drug revenue predictions to 2023. You find data, trends, opportunities and commercial...

2014-04-30 12:30:17

- First results of the pivotal Phase 3 INPULSIS(TM) trials investigating the efficacy and safety of nintedanib, an investigational compound, in the treatment of idiopathic pulmonary fibrosis (IPF) RIDGEFIELD, Conn., April 30, 2014 /PRNewswire/ -- Boehringer Ingelheim announced today that the first results from two highly anticipated Phase 3 trials in idiopathic pulmonary fibrosis (IPF) and in chronic obstructive pulmonary disease (COPD) will be presented at the 2014 American...

2014-04-11 12:24:06

DUBLIN, Ireland, April 11, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/53hl65/global) has announced the addition of the "Global Epinephrine Auto-Injector Market Report" [http://www.researchandmarkets.com/research/53hl65/global ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The analysts forecast the Global Epinephrine Auto-injector market to grow at a CAGR of 13.34 percent over the...

2014-03-28 12:22:00

DUBLIN, Mar. 28, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/8gxjqj/investigation ) has announced the addition of the "Investigation Report on China's Tiotropium Bromide Market, 2009-2018" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) As the air becomes more contaminated, incidence of asthma and chronic obstructive pulmonary diseases also increases. Consequently, more market space is provided for relevant drug...


Word of the Day
kenspeckle
  • Having so marked an appearance as easily to be recognized.
This word may come from the Swedish 'kanspak,' quick at recognizing persons or things, or else from confusion with 'conspicuous.'